After days of speculation, Merck & Co confirmed today that it has agreed to acquire Acceleron Pharma $1.5 billion, setting up what could be one of the largest biopharma acquisitions of 2021 so far.

Merck's $11.5 billion deal to acquire Acceleron last year hinged on the promise of pulmonary arterial hypertension (PAH) candidate sotatercept, which has just hit the spot in a much-anticipated phase ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery, development, and commercialization of TGF-beta superfamily therapeutics to ...

Acceleron Pharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. It offers REBLOZYL, an erythroid ...

Merck spent a small fortune on the acquisition of Acceleron Pharma, and so far, it's paying off. Recent phase 2 data suggests the pharmaceutical giant could get even more bang for its buck. Despite ...

Classical computing has inherent limitations in capturing cellular dynamics. This Roadmap article discusses how recent advancements in quantum computing could overcome bottlenecks in spatiotemporal ...

Whether you're looking to get ahead in your schoolwork, improve a business skill, edit video, or even master French pastry, the top online learning sites we've tested can help. I'm an expert in ...